We are live on
!
Find out more
Boston Partners Portfolio holdings
AUM
$113B
1-Year Est. Return
38.87%
This Fund
S&P 500
This Quarter
Est. Return
-14.15%
1 Year Est. Return
+38.87%
3 Year Est. Return
+108.29%
5 Year Est. Return
+142.95%
10 Year Est. Return
+500.61%
AUM
$69.6B
AUM Growth
-$16.5B
(-19%)
Cap. Flow
-$3.3B
Cap. Flow
% of AUM
-4.75%
Top 10 Holdings %
Top 10 Hldgs %
17.71%
Holding
779
New
83
Increased
294
Reduced
313
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$753M |
| 2 |
Marathon Petroleum
MPC
|
+$374M |
| 3 |
Target
TGT
|
+$361M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$299M |
| 5 |
Huntington Bancshares
HBAN
|
+$242M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ANDV
Andeavor
ANDV
|
+$1.05B |
| 2 |
Merck
MRK
|
+$702M |
| 3 |
Bank of America
BAC
|
+$542M |
| 4 |
Oracle
ORCL
|
+$528M |
| 5 |
Steel Dynamics
STLD
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 26.74% |
| 2 | Healthcare | 14.95% |
| 3 | Industrials | 13.38% |
| 4 | Technology | 12.24% |
| 5 | Energy | 6.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class B
BRK.B
$1.08T
| $1.64B | 2.36% |
8,030,767
-43,267
| -0.5% | -$9.04M |
|
2
Johnson & Johnson
JNJ
$640B
| $1.61B | 2.32% |
12,486,839
-541,478
| -4% | -$75.5M |
|
3
Cisco
CSCO
$442B
| $1.45B | 2.08% |
33,457,502
-960,736
| -3% | -$44M |
|
4
Pfizer
PFE
$160B
| $1.24B | 1.78% |
29,850,436
-220,849
| -0.7% | -$9.17M |
|
5
JPMorgan Chase
JPM
$942B
| $1.22B | 1.76% |
12,539,398
-3,193,863
| -20% | -$340M |
|
|
6
Bank of America
BAC
$428B
| $1.14B | 1.63% |
46,087,680
-19,963,727
| -30% | -$542M |
|
7
Comcast
CMCSA
$93.7B
| $1.08B | 1.56% |
31,823,642
-1,292,576
| -4% | -$47.2M |
|
8
Wells Fargo
WFC
$257B
| $1.04B | 1.49% |
22,520,875
-721,376
| -3% | -$36.9M |
|
9
Citigroup
C
$223B
| $1.02B | 1.46% |
19,502,094
-3,814,177
| -16% | -$242M |
|
10
Verizon
VZ
$205B
| $891M | 1.28% |
15,857,072
-483,130
| -3% | -$27.4M |
|
11
HP
HPQ
$26.7B
| $888M | 1.28% |
43,404,835
+2,215,865
| +5% | +$51.7M |
|
12
CVS Health
CVS
$119B
| $811M | 1.17% |
12,382,737
+932,601
| +8% | +$69.6M |
|
13
Microsoft
MSFT
$3.75T
| $800M | 1.15% |
7,881,016
+14,149
| +0.2% | +$1.52M |
|
14
Allstate
ALL
$65.1B
| $784M | 1.13% |
9,485,145
-1,783,509
| -16% | -$160M |
|
15
Chevron
CVX
$392B
| $780M | 1.12% |
7,170,863
-92,061
| -1% | -$10.7M |
|
|
16
Procter & Gamble
PG
$333B
| $775M | 1.11% |
+8,428,522
| New | +$753M |
|
17
Chubb
CB
$131B
| $752M | 1.08% |
5,823,366
+520,391
| +10% | +$67.2M |
|
|
DFS
18
DELISTED
Discover Financial Services
DFS
| $733M | 1.05% |
12,420,880
-255,588
| -2% | -$17.6M |
|
|
19
Marathon Petroleum
MPC
$102B
| $718M | 1.03% |
12,173,365
+5,479,818
| +82% | +$374M |
|
20
RTX Corp
RTX
$286B
| $707M | 1.02% |
10,545,419
+34,093
| +0.3% | +$2.68M |
|
21
Elevance Health
ELV
$86.6B
| $701M | 1.01% |
2,669,935
-15,482
| -0.6% | -$4.26M |
|
22
Cigna
CI
$73.4B
| $690M | 0.99% |
3,633,997
+289,480
| +9% | +$60.4M |
|
23
Medtronic
MDT
$115B
| $671M | 0.96% |
7,377,001
+734,286
| +11% | +$68.6M |
|
24
Boeing
BA
$166B
| $629M | 0.9% |
1,951,632
+123,895
| +7% | +$42.8M |
|
25
KeyCorp
KEY
$23.5B
| $610M | 0.88% |
41,244,050
+10,713,851
| +35% | +$189M |
|
Similar funds
Boston Partners's Q4 2018 Portfolio in Review
As of Q4 2018, Boston Partners held 779 positions worth $69.6B, down 19% from $86.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Boston Partners withdrew a net $3.3B in Q4 2018, closing 76 positions and reducing 313 holdings. Its most notable exit was Andeavor, an estimated $1.05B position sold in full.
By sector, the portfolio is most concentrated in Financials at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Boston Partners opened a new position in Procter & Gamble worth $775M.
- Boston Partners's largest Q4 2018 buy was Procter & Gamble: 8,428,522 shares worth $775M.
- Boston Partners added most to Marathon Petroleum in Q4 2018, an estimated $374M increase.
- Boston Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $702M.
- Boston Partners fully exited Andeavor in Q4 2018, selling an estimated $1.05B.
- Boston Partners's ten largest holdings make up 18% of its $69.6B portfolio in Q4 2018.
- Boston Partners opened 83 new positions and closed 76 in Q4 2018.
- Boston Partners's portfolio value fell 19% quarter-over-quarter to $69.6B.
Based on Boston Partners's 13F filing for Q4 2018, filed 7 Feb 2019.